Tonix Pharmaceuticals Holding Corp.

NASDAQ:TNXP

Biotechnology

Healthcare
$2.82 -1.97%

-$0.24 today

Market cap
$54.80M
Beta
1.68
P/E (TTM)
-1.1
EPS (TTM)
-$10.75
52W Low $10.03High $69.97

Volume 1.04M

Average 0.49M

TNXP Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Tonix Pharmaceuticals Holding Corp.NASDAQ: TNXP

Operating Income · Q1 FY2026 · quarter ended Mar 2026

Operating income remains negative

Q1 FY2026 operating income was -$41.54M, compared with -$16.05M a year earlier. Trailing-twelve-month operating income was -$151.19M.

Context

  • Operating income amounted to 959.1% of revenue in FY2025, down 395.2 pp from a year earlier.
  • Operating income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether operating income reaches the consensus estimate from 2 analysts of -$89.85M (+28.5%) for the fiscal year ending Dec 2026, a step up from the +8.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$41.54M+14.0% QoQ
Last fiscal yearDec 2025
-$125.7M+8.0% YoY
LTMMar 2026
-$151.19M-108.7% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-158.7%-72.2%+86.5 pp
1 year+8.0%+28.5%+20.5 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(125.7M) USD
Year-over-year change
+8.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How TNXP compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -108.7% is the lowest of 10, against a peer median of -3.6%.
  • Operating income amounts to 861.2% of revenue for TNXP, versus a peer median of 3669.4%.
TNXP Competitors
Operating Income for TNXP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ELTXElicio Therapeutics, Inc.LTM Mar 2026-$37.58M USD+17.4%——
IPHAInnate Pharma S.A.FY2025-€53.43M EUR-3.6%—1916.9%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026-$65.46M USD-25.5%—3669.4%
FBRXForte Biosciences, Inc.LTM Mar 2026-$76.97M USD-71.3%——
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-$79.16M USD-57.0%—134164.4%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026-$86.47M USD-11.3%——
MCRBSeres Therapeutics, Inc.LTM Mar 2026-$87.64M USD+23.2%—7641.0%
NKTXNkarta, Inc.LTM Mar 2026-$116.31M USD+11.9%——
FATEFate Therapeutics, Inc.LTM Mar 2026-$139.42M USD+30.5%—2207.5%
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026-$151.19M USD-108.7%—861.2%
Peer median (excluding TNXP) —-3.6%—3669.4%

Competitors are the stored peer set for TNXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue007.77M10.09M13.11M
Cost of Revenue004.74M7.77M8.57M
Gross Profit003.03M2.33M4.54M
Gross Margin——39.0%23.1%34.7%
Research & Development68.84M81.88M86.66M40.45M44.49M
Selling, General & Admin23.47M30.22M34.75M40.1M85.76M
Operating Expenses92.31M112.09M121.41M139.03M130.25M
Depreciation & Amortization50K1.25M4.29M3.42M1.93M
EBITDA(92.24M)(108.97M)(112.37M)(74.32M)(122.01M)
EBITDA Margin——-1446.5%-736.3%-930.9%
Operating Income(92.31M)(112.09M)(118.38M)(136.7M)(125.7M)
Operating Margin——-1523.9%-1354.3%-959.1%
Interest Income25K1.87M004.15M
Interest Expense000089K
Other Income / Expenses25K1.87M1.72M6.67M1.68M
Income Before Tax(92.29M)(110.22M)(116.66M)(130.04M)(124.02M)
Pre-Tax Margin——-1501.8%-1288.3%-946.2%
Income Tax Expense00000
Net Income(92.29M)(110.22M)(116.66M)(130.04M)(124.02M)
Net Margin——-1501.8%-1288.3%-946.2%
EPS (Basic)(163,968.00)(811.68)(6,368.84)(176.60)(14.57)
EPS (Diluted)(163,968.00)(811.68)(6,368.84)(176.60)(14.57)
Weighted Avg Shares5633.07M1.83M2.26M8.51M
Weighted Avg Shares (Diluted)5633.07M1.83M2.26M8.51M

Tonix Pharmaceuticals Holding Corp.

NASDAQ:TNXP

Intrinsic Alpha fair value

Locked

Current Price

$2.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.